This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

ACRODAT privacy and Information Governance

Frequently asked questions about privacy and Information Governance

Is a mobile application required for this asset?

  • No – ACRODAT is an online software which requires no installation and can be accessed simply via a URL.

What type of personal data is collected?

  • End user data: healthcare professional email address, password, healthcare professional name and surname, clinic name.
  • Patient data: Patient e-mail address, patient ID, patient initials, year of birth, gender, diagnosis, visit date, IGF-1 levels and normal range, tumour status, comorbidities, symptoms, health related quality of life (ACROQoL), treatment change (if any) and reason.

Is the processing adequate, relevant and limited to what is necessary (data minimisation)?

  • Yes, data minimisation has been considered and patient ID is the only mandatory field.

Who is the data controller?     

  • The centre is the exclusive data controller. It is their responsibility to ensure patient data’s accuracy and explain to patients how their data are stored/used.
  • Pfizer is the data controller of the end user data.

Can information be deleted?     

  • Yes, healthcare professionals can request the support team for their account to be deleted and delete patient’s data any time.

Can a patient’s NHS number be used for their ID?     

  • Yes, this may help centres to compare ACRODAT records to information on their own databases such as patient notes.

How will this information be used? How will Pfizer specifically be using this information?     

  • The patient information will be used by the centre to enhance clinical decision making. Due to data being in one place, it will then be quicker to assess during consultations. Graphs can be shared with the patient as a tool to explain treatment and outcomes.
  • Pfizer uses clinic and End User (physician) data:
  • (a) for the registration and administration of Clinic / End User accounts and providing access to authorised End Users;
  • (b) to track and assess use of ACRODAT by de-identified data;
  • (c) to send notifications of application outages or updates (including suspensions of End User accounts and withdrawal of ACRODAT);
  • (d) to respond to requests for support; and
  • (e) to record details of which End User account has been used to create, view and update any patient records and/or End User data.

What is the legal basis for the processing/sharing of the information?    

  • Consent.

How can patient consent be captured?     

  • It is the centre’s responsibility to inform the patient about the collection, storage and processing of their data and obtain consent. We can provide a consent advice template to help with this process, just ask your local representative to find out more.

Who will have access to patient information and what controls are in place to protect this information?     

  • Any healthcare professional with access to ACRODAT at the same centre can view the patient information entered into the tool. The third-party provider of the tool, Kelyon, will also have access to the patient information. Kelyon is ISO 27001 certified (Amazon AWS provider) and abides by multiple security controls and policies.

What information/data will Pfizer have access to?     

  • Pfizer does not have access to information which could identify the patient. All patient information is anonymised by the third-party provider, Kelyon, and is aggregated to provide Pfizer with the following statistics; (i) the number of End Users of ACRODAT within the UK, and (ii) the number of patients with whom ACRODAT has been used. Pfizer will use these statistics in order to assess how ACRODAT is used and to improve its functionality and performance.

Who will be responsible for monitoring the contract with the third-party supplier?     

  • Pfizer.

What information sharing protocols and operational agreements exist with the third-party processor, Kelyon?     

  • ISO 27001 certifies (Amazon AWS provider)
  • Kelyon Information Security Policy rev.2
  • Kelyon User and Access Administration rev1
  • Kelyon BCP Business Continuity Plan

Will the third-party processor, Kelyon, access, process or host the data in compliance with the Data Protection Act?     

  • Yes.

Which are the conditions for transfer to third countries or international organisations?     

  • Kelyon is registered and holds data in EEA. Information is not transferred or processed outside of this area.

A guide to using ACRODAT

Learn more about the development of ACRODAT, how to add and evaluate patients and more in the ACRODAT user guide

Download the guide
Request an ACRODAT demo

Help find your patients' personal optimum by titrating doses

Learn more

Explore more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits

Contact us

Treatment impact on the tumour

Professor Richard Ross, Consultant Endocrinologist, University of Sheffield, discusses the various treatments for acromegaly and how they each impact the pituitary tumour.

Learn more

PP-SOM-GBR-1013. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No